Clinical Trial Update: Low-dose Dasiglucagon for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes [Phase 2]

View source ↗

Summary

Phase 2 trial assessing low-dose dasiglucagon to prevent insulin-induced hypoglycemia in people with type 1 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoglycemia
• Type 1 Diabetes Mellitus

Drugs mentioned

• dasiglucagon (dasiglucagon)

Snippet

Sponsor: Steno Diabetes Center Copenhagen | Conditions: Type 1 Diabetes, Hypoglycemia | Phase 2 | Status: COMPLETED